Hepatitis E virus is effectively inactivated by methylene blue plus light treatment. 2022

Ute Gravemann, and Michael Engelmann, and Volker Kinast, and Thomas Burkard, and Patrick Behrendt, and Torsten J Schulze, and Daniel Todt, and Eike Steinmann
German Red Cross Blood Service NSTOB, Springe, Germany.

Photodynamic treatment with methylene blue (MB) and visible light is a well-established pathogen inactivation system for human plasma. This technique is routinely used in different countries. MB/light treatment was shown to inactivate several transfusion-transmittable viruses, but its efficiency for the inactivation of the quasi-enveloped hepatitis E virus (HEV) has not yet been investigated. Plasma units were spiked with cell culture-derived HEV and treated with the THERAFLEX MB-Plasma system using various light doses (30, 60, 90, and 120 J/cm2 ). HEV titers in pre- and post-treatment samples were determined by virus titration and a large-volume plating assay to improve the detection limit of the virus assay. THERAFLEX MB-Plasma efficiently inactivated HEV in human plasma. Even the lowest light dose of 30 J/cm2 inactivated HEV down to the limit of detection, with a mean log reduction factor of greater than 2.4 for the total process. Our study demonstrates that the THERAFLEX MB-Plasma system effectively inactivates HEV in human plasma.

UI MeSH Term Description Entries
D008027 Light That portion of the electromagnetic spectrum in the visible, ultraviolet, and infrared range. Light, Visible,Photoradiation,Radiation, Visible,Visible Radiation,Photoradiations,Radiations, Visible,Visible Light,Visible Radiations
D008751 Methylene Blue A compound consisting of dark green crystals or crystalline powder, having a bronze-like luster. Solutions in water or alcohol have a deep blue color. Methylene blue is used as a bacteriologic stain and as an indicator. It inhibits GUANYLATE CYCLASE, and has been used to treat cyanide poisoning and to lower levels of METHEMOGLOBIN. Methylthionine Chloride,Swiss Blue,Basic Blue 9,Chromosmon,Methylene Blue N,Methylthioninium Chloride,Urolene Blue,Blue 9, Basic,Blue N, Methylene,Blue, Methylene,Blue, Swiss,Blue, Urolene
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014466 Ultraviolet Rays That portion of the electromagnetic spectrum immediately below the visible range and extending into the x-ray frequencies. The longer wavelengths (near-UV or biotic or vital rays) are necessary for the endogenous synthesis of vitamin D and are also called antirachitic rays; the shorter, ionizing wavelengths (far-UV or abiotic or extravital rays) are viricidal, bactericidal, mutagenic, and carcinogenic and are used as disinfectants. Actinic Rays,Black Light, Ultraviolet,UV Light,UV Radiation,Ultra-Violet Rays,Ultraviolet Light,Ultraviolet Radiation,Actinic Ray,Light, UV,Light, Ultraviolet,Radiation, UV,Radiation, Ultraviolet,Ray, Actinic,Ray, Ultra-Violet,Ray, Ultraviolet,Ultra Violet Rays,Ultra-Violet Ray,Ultraviolet Black Light,Ultraviolet Black Lights,Ultraviolet Radiations,Ultraviolet Ray
D016752 Hepatitis E virus A positive-stranded RNA virus species, causing enterically-transmitted non-A, non-B hepatitis (HEPATITIS E). Hepatitis E virus (strain Burma),Orthohepevirus A,Paslahepevirus,Paslahepevirus balayani,Paslahepeviruses
D038301 Virus Inactivation Inactivation of viruses by non-immune related techniques. They include extremes of pH, HEAT treatment, ultraviolet radiation, IONIZING RADIATION; DESICCATION; ANTISEPTICS; DISINFECTANTS; organic solvents, and DETERGENTS. Viral Inactivation,Inactivation, Viral,Inactivation, Virus

Related Publications

Ute Gravemann, and Michael Engelmann, and Volker Kinast, and Thomas Burkard, and Patrick Behrendt, and Torsten J Schulze, and Daniel Todt, and Eike Steinmann
October 2020, Vox sanguinis,
Ute Gravemann, and Michael Engelmann, and Volker Kinast, and Thomas Burkard, and Patrick Behrendt, and Torsten J Schulze, and Daniel Todt, and Eike Steinmann
May 2013, Transfusion,
Ute Gravemann, and Michael Engelmann, and Volker Kinast, and Thomas Burkard, and Patrick Behrendt, and Torsten J Schulze, and Daniel Todt, and Eike Steinmann
June 2000, British journal of haematology,
Ute Gravemann, and Michael Engelmann, and Volker Kinast, and Thomas Burkard, and Patrick Behrendt, and Torsten J Schulze, and Daniel Todt, and Eike Steinmann
June 1993, Infusionstherapie und Transfusionsmedizin,
Ute Gravemann, and Michael Engelmann, and Volker Kinast, and Thomas Burkard, and Patrick Behrendt, and Torsten J Schulze, and Daniel Todt, and Eike Steinmann
September 2016, Transfusion,
Ute Gravemann, and Michael Engelmann, and Volker Kinast, and Thomas Burkard, and Patrick Behrendt, and Torsten J Schulze, and Daniel Todt, and Eike Steinmann
November 1998, Journal of medical virology,
Ute Gravemann, and Michael Engelmann, and Volker Kinast, and Thomas Burkard, and Patrick Behrendt, and Torsten J Schulze, and Daniel Todt, and Eike Steinmann
June 2004, Transfusion,
Ute Gravemann, and Michael Engelmann, and Volker Kinast, and Thomas Burkard, and Patrick Behrendt, and Torsten J Schulze, and Daniel Todt, and Eike Steinmann
August 1992, Proceedings of the National Academy of Sciences of the United States of America,
Ute Gravemann, and Michael Engelmann, and Volker Kinast, and Thomas Burkard, and Patrick Behrendt, and Torsten J Schulze, and Daniel Todt, and Eike Steinmann
January 1993, Molecular & general genetics : MGG,
Ute Gravemann, and Michael Engelmann, and Volker Kinast, and Thomas Burkard, and Patrick Behrendt, and Torsten J Schulze, and Daniel Todt, and Eike Steinmann
November 1987, The Journal of urology,
Copied contents to your clipboard!